Sanofi (SNY) Will Outline Long-Term Roadmap; Sees Sales CAGR at 3% - 4% from 2015 -20
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St futures muted as investors monitor US-Iran negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
UBS Downgrades Sanofi (SNY) to Neutral
November 9, 2015 8:45 AM ESTUBS downgraded Sanofi (NYSE: SNY) from Buy to Neutral.
For an analyst ratings summary and ratings history on Sanofi click here. For more ratings news on Sanofi click here.
Shares of Sanofi closed at $46.60 yesterday.
... MoreSanofi (SNY), Lexicon Pharma (LXRX) Enter Sotagliflozin Commercialization, Development Agreement
November 6, 2015 6:26 AM ESTSanofi (NYSE: SNY) and Lexicon Pharma (Nasdaq: LXRX) announced that they have entered into a collaboration and license agreement for the development and commercialization of sotagliflozin, an investigational new oral dual inhibitor of sodium-glucose cotransporters 1 and 2 (SGLT-1 and SGLT-2), which could be a potential treatment option for people with diabetes.
"This agreement with Lexicon reinforces our commitment to helping people living with diabetes," said Pascale Witz, Executive Vice President, Sanofi, who will lead the Global Diabetes and Cardiovascular Care Business Unit in the company's new organizational structure. "Adding... More
MannKind (MNKD) Drops to Session Lows on Sanofi-Related Chatter
November 5, 2015 11:53 AM ESTMannKind (NASDAQ: MNKD) dropped to session lows Thursday, falling 11%. Chatter suggests the fall is tied to a meeting at Sanofi (NYSE: SNY) tomorrow, and possible fallout for MannKind given sluggish Afrezza sales.
Senior management representatives at... More
